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Background: The aim of this study was to measure the biological characteristics involved in tumorigenesis and the
progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences.
Methods: For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities
in a series of 130 symptomatic and 161 screen-detected tumors.
Results: After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic
cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96)
and had high estrogen and progesterone receptor concentrations more often than did symptomatic cancers
(OR = 3.38, CI = 1.72-6.63 and OR = 3.44, CI = 1.94-6.10, respectively). Furthermore, the expression of bcl-2, a marker
of good prognosis in breast cancer, was higher and HER2/neu expression was lower in screen-detected cancers
than in symptomatic cancers (OR = 1.77, CI = 1.01-3.23 and OR = 0.64, CI = 0.40-0.98, respectively). However, when
comparing prevalent vs incident screen-detected carcinomas, prevalent tumors were larger (OR = 2.84, CI = 1.05-
7.69), were less likely to be HER2/neu positive (OR = 0.22, CI = 0.08-0.61) and presented lower Ki67 expression
(OR = 0.36, CI = 0.17-0.77). In addition, incident tumors presented a shorter survival time than did prevalent ones
(RR = 4.88, CI = 1.12-21.19).
Conclusions: Incident carcinomas include a variety of screen-detected carcinomas that exhibit differences in
biology and prognosis relative to prevalent carcinomas. The detection method is important and should be taken
into account when making therapy decisions.
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The widespread introduction of mammographic screen-
ing for breast cancer has led to a 20% reduction in
breast cancer mortality [1]. Tumors detected by mam-
mographic screening are generally considered to have
good prognoses because of several biases, such as selec-
tion bias, lead-time bias, length bias, and, possibly, over-
diagnosis (some tumors might never have surfaced) [2].
In support of these observations autopsy studies have
revealed occult breast cancer in 1.3% and in situ* Correspondence: mredondo@hcs.es
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reproduction in any medium, provided the orcarcinoma in 8.9% –18% of women [3,4]. However, it is
impossible to determine the natural history of these
tumors. Screening will inevitably detect a greater pro-
portion of slower-growing, better-prognosis cancers than
those observed in the symptomatic population. The re-
mainder of the survival advantage is likely to be due to
additional biological differences between screen-detected
and symptomatic cancers, including rates of hormone
receptor positivity and proliferation and other biological
factors [5].
Therefore, screening enables the detection of breast
cancers at an earlier stage of disease. It is now well
documented that screen-detected cancers are generally
smaller, of lower grade and less likely to have axillary
lymph node involvement [6].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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breast cancer have been identified. The important patho-
logical features of prognostic significance are tumor size
and the presence of lymph node metastases. In symp-
tomatic breast cancer, the presence of lymph node me-
tastases is generally considered to be the most important
prognostic factor. In screen-detected cancers, however,
the incidence of tumors with lymph node involvement is
low because of earlier diagnosis and the smaller size of
the tumor and is, therefore, of limited prognostic value.
Fixing the size of the tumor (by comparing same-size
tumors) reduces the lead-time bias. More important is
the possible impact of length bias. It is theoretically pos-
sible to eliminate length bias by adjusting for the aggres-
siveness of tumors on the basis of a full biological
description [5,7,8].
At present, cancer detection based on mammography
screening is not considered to be of significant import-
ance when assessing the risk of breast cancer recurrence
or in decision making concerning the need for adjuvant
therapies in the diagnosis of early breast cancer. If can-
cerous tumors detected by mammography screening
were associated with better outcomes than tumors of
similar size detected by methods other than screening,
women with a lower risk of recurrence might be sub-
jected to adjuvant therapies. Recent studies have shown
that screen detection remains an independent prognostic
factor after adjusting for disease stage [5,7-9].
This paper, therefore, examines whether a cancer
detected by mammographic screening confers additional
prognostic benefit to the patient over and above that
expected by the improved stage shift. In addition, the
pathologic features of breast cancer diagnosed in a first
screening round (prevalent) were compared with those
of incident cases on the basis that prevalent cancers have
a potentially longer period over which to develop prior
to detection than incident cancers, for which this period
is theoretically limited by the screening interval.
Several studies have reported that tumors detected be-
tween mammography screening rounds (interval can-
cers) are similar to those found outside screening
programs [10,11]. However, it has not been shown that a
cancer detected at a round subsequent to one or more
screens (incident tumors) has a different biology and
outcome from tumors detected in the first round (preva-
lent tumors) or outside the screening program.
Material and methods
Patients and samples
A nested case–control study was performed among
woman who were histologically diagnosed with breast
cancer and who had undergone surgical resection be-
tween 1996 and 2007. Thus, the study population con-
sisted of 291 patients referred to the symptomatic (n =130) and screening (n = 161) services of Costa del Sol
Hospital. The symptomatic clinic was attended by
patients who were referred with breast abnormalities,
typically palpable lesions, by their primary care physi-
cians. There were no differences in mean patient age be-
tween screen-detected and symptomatic carcinomas
(56.33 ± 1.14 vs. 56.73 ± 1.18) (Table 1).
In general, following an initial screen, women are
invited to attend rescreening at intervals of two years,
while annual screens are offered to individuals with a
clinical indicator of increased breast cancer risk detected
at screening or who had a first-degree relative with a his-
tory of breast cancer. This study was approved by the
Costa del Sol Hospital ethics committee, and informed
consent was obtained to supply tumor material for patho-
logic evaluation and immunohistochemical analyses.
Cancers diagnosed at the initial screening episode were
designated as prevalent. Cancers diagnosed at a round
subsequent to one or more screens in which cancer was
not detected were classed as incident. All mammograms
were reviewed to confirm incident tumors. In our series,
there were 76 prevalent tumors, 65 incident tumors, and
we also considered a third group, false negative mammo-
grams, which included those tumors that were present
in the first round but were not detected (n = 20).
Interval cancers, defined as cancers detected within
24 months after a negative mammogram but before the
following invited screening, were excluded from this
study. Furthermore, patients who received pre-operative
adjuvant therapy were excluded from the study. In situ
carcinomas were also excluded from the survival
analysis.
In the survival studies, our primary endpoint was time
to recurrence or breast cancer-specific death as mea-
sured from the time of diagnosis. Survival times of
patients still alive or who died of other causes were cen-
sored as of the date of the last follow-up. Follow-up was
conducted by the Hospital Tumor Registry and was
achieved for 93.7% of patients with a median follow-up
period of 71 months.
Finally, we considered treatment delay, which was
defined as a delay of longer than one month between
diagnosis and the first treatment.
All specimens were fixed in 10% neutral buffered for-
malin and embedded in paraffin. The following clinical
and histopathological data were collected from all cases:
patient age at diagnosis, differentiation degree, hormonal
receptor status, tumor size, presence of regional (lymph
node) metastases, tumor stage and patient survival.
Pathological staging was performed according to the
postsurgical International Union Against Cancer
Tumor-Node-Metastasis classification. The histological
typing and grading of the tumors was performed accord-
ing to the World Health Organization classification.
Table 1 Clinical-pathological prognostic features of disease
Screen-detected (n = 161) vs. Symptomatic (n = 130) P value OR adjusted by tumor size
Mean age 56.33 ± 1.14 vs. 56.73 ± 1.18 N.S. 1.03 (0.99-1.05)
Mean size (cm) 1.62 + 0.14 vs. 2.68 + 0.15 p < 0.001 –
Lymph node positive 22.3% vs. 48.9% p < 0.001 0.54 (0.31-0.95)
Poorly differentiated tumors 33.1% vs. 39.7% N.S. 0.75 (0.47-1.20)
ER positive 87.8% vs. 57.4% p < 0.001 4.76 (2.50-9.09)
PR positive 73.1% vs. 36.4% p < 0.001 4.16 (2.43-7.14)
In situ carcinomas 11.4% vs.1.5% p < 0.001 6.25 (1.35-33.3)
Apoptosis 48.8% vs. 38.5% N.S. 1.53 (0.84-2.77)
Bcl-2 78.4% vs. 62.7% p < 0.01 1.92 (1.08-3.44)
c-erb-B2 14.6% vs. 26.3% p < 0.05 0.57 (0.15-0.97)
Ki67 46.7% vs. 52.5% N.S. 0.97 (0.57-1.63)
Delay Diagnosis- treatment (>30 days) 47.5% vs. 57% N.S. 0.75 (0.46-1.25)
ER: estrogen receptor, PR: progesterone receptor.
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nomas and 61 tumors belonged to other histological
subtypes.
HercepTest IHC assay
In this study, HER2/neu protein expression was eva-
luated using the HercepTest for Immunoenzymatic
Staining at PPL according to the protocol described in
the manufacturer's guide accompanying the kit. Tissue
sections were deparaffinized in two 5-minute changes of
xylene and were rehydrated using a gradient of alcohols
culminating in distilled water. Subsequently, the slides
were immersed in Dako Epitope Retrieval Solution
(Dako, Copenhagen, Denmark, 0.01 mol/L citrate buffer;
pH = 6) that had been preheated to 95°C; then, this solu-
tion was heated in a water bath at 95°C for a total of
40 minutes, followed by a 20-minute cool-down period
at room temperature. The slides were incubated with
the primary rabbit polyclonal antibody to the HER2/neu
oncoprotein (as supplied prediluted in the HercepTest
kit) on a Dako Autostainer for 30 minutes at room
temperature. The antibody was localized by incubating
the slides with the Dako Visualization Reagent (dextran
polymer conjugated with horseradish peroxidase and
goat anti-rabbit immunoglobulins) for 30 minutes using
the Dako Autostainer. Diaminobenzidine (DAB) was
used as the chromogen, and the sections were counter-
stained with hematoxylin. Positive controls were
included in each staining run and consisted of freshly
cut breast cancer cases known to express HER-2/neu
and a control slide consisting of three pelleted, formalin-
fixed, paraffin-embedded human breast cell lines with
staining intensity scores of 0, 1+, and 3+ (supplied in the
HercepTest kit). Negative controls consisted of substi-
tuting normal rabbit serum (Dako Negative Control Re-
agent) for the HER-2/neu primary antibody. Onlymembrane staining intensity and pattern were evaluated
using the 0 to 3+ scale, as illustrated in the HercepTest
kit scoring guidelines. As defined in the HercepTest kit
guide, scores of 0 or 1+ were considered negative for
HER2/neu overexpression, 2+ was considered weak posi-
tive, and 3+ was considered strong positive. To qualify
for 2+ and 3+ scoring (i.e., positive), complete mem-
brane staining of more than 10% of tumoral cells had to
be observed.
We also used a modification of this scoring system
that took into consideration the level of staining of non-
neoplastic epithelium present on the same slide as the
cancer. In this system, nonneoplastic epithelium was also
graded on a 0 to 3+ scale using the same criteria used
for the assessment of tumoral cell staining. Cases were
considered HER2/neu positive only when the difference
between the tumoral cell staining score and the nonneo-
plastic epithelial cell staining score was 2.Immunohistochemistry
We studied tumor proliferation and the expression of
hormone receptors and proteins related to the apoptotic
process by detecting the expression of Ki67, HER2/neu,
estrogen receptors, progesterone receptors and bcl-2
(Dako, Copenhagen, Denmark).
One representative block from each patient was sec-
tioned at 5 μm and stained with the primary antibody. A
standard, three-step technique using an avidin-biotin-
complex/horseradish peroxidase (HRP) kit (Dako) was
used as described previously [12]. For the negative control,
the primary antibodies were replaced with phosphate-
buffered saline (PBS). Tumors and tissues with known
staining patterns were used as positive immunostaining
controls. Mononuclear infiltrates were used as positive in-
ternal controls for bcl-2.
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of the tumors, and the reported values represent the
means of the areas measured. Expression was scored as
follows: negative if no staining was observed or if immu-
noreactivity was observed in less than 10% of the tumor
cells and positive if more than 10% of the tumor cells
showed staining with an intensity >1 (maximum value = 3).
Samples were analyzed and scored blindly.
Scoring was performed by two independent observers,
and discrepant results were discussed over a double-
headed microscope.In situ localization of apoptotic cells
To detect apoptotic cells, in situ labeling of the 3'-ends
of the DNA fragments generated by apoptosis-associated
endonucleases was performed using a commercial apop-
tosis detection kit (Roche Diagnostic, Germany). Briefly,
deparaffinized sections were incubated with 20 μg/ml of
proteinase K (Sigma Chemical Co. St. Louis, MO) for
15 min. Following rinsing in PBS, the slides were cov-
ered with terminal deoxynucleotidyl transferase plus a
nucleotide mixture at a 1:35 dilution for 60 min at 37°C.
Then, the slides were covered with an anti-fluorescein
antibody conjugated with alkaline phosphatase. After
substrate reaction, the stained cells were analyzed under
a light microscope. Pretreatment of sections with DNase
served as a positive control for the enzymatic proce-
dures; omission of the enzyme served as a negative
control.
Established morphological features used to identify
apoptosis on H&E were also required in TUNEL-stained
slides. Cells were defined as apoptotic if the entire nu-
clear area of the cell was positively labeled. Apoptotic
bodies were defined as small, positively labeled globular
bodies in the cytoplasm of the tumor cells that could be
found either singularly or in groups.
One thousand cells were counted for each specimen.
The number of positively stained cells was then divided
by 1000 to estimate the percentage of apoptotic cells in
each specimen. We used the mean level of apoptosis in
our series (1%) (range 0.01-10.8%) as a cut-off.Statistical analysis
Differences between the detection groups with regard to
patient characteristics, including clinical, biological and
histopathological variables, were analyzed via cross-
tabulation (Fisher’s exact test) for categorical variables
and analysis of variance for continuous variables (natural
log transformed when necessary). Survival curves were
generated using the Kaplan-Meier method, and statis-
tical testing was performed using the log-rank test.
Multivariate analyses and HR calculations with 95% CIs
were performed using the Cox proportional hazardsmodel. All computations were executed using SPSS soft-
ware (Chicago, IL). All P values are two-sided.Results
Symptomatic versus screen-detected carcinomas
Screen-detected patients had persistently smaller tumors
(1.62 ± 0.14 vs. 2.68 ± 0.15, p < 0.001), a lower rate of
axillary node metastases (22.3% vs. 48.9%, p < 0.001) and
a higher percentage of in situ carcinomas (11.4% vs.
1.5%, p < 0.001). We also found biological differences be-
tween the two groups. Screen-detected tumors were
more frequently estrogen receptor and progesterone re-
ceptor positive (87.8% vs. 57.4%, p < 0.001 and 73.1% vs.
36.4%, p < 0.001, respectively), presented a higher ex-
pression of bcl-2 protein (78.4% vs. 62.7%, p < 0.01) and
were less frequently HER2/neu positive (14.6% vs. 26.3%,
p < 0.05) (Table 1). These relationships were maintained
when in situ carcinomas were excluded from the analysis
(data not shown).
After adjustment for the smaller size of the screen-
detected primary tumors compared with control cancers,
the differences between the two groups were maintained
and related to axillary nodal metastases (OR = 0.25; CI =
0.13-0.47), percentage of in situ carcinomas (OR = 6.19,
CI = 1.35-28.37) and estrogen and progesterone receptor
expression (OR = 3.38, CI = 1.72-6.63; OR = 3.44, CI =
1.94-6.10, respectively). Furthermore, the expression of
bcl-2 was higher (OR = 1.77, CI = 1.01-3.23) and that of
HER2/neu was lower in screen-detected cancers com-
pared with symptomatic ones (Table 1).
When prevalent and incident tumors were separated
and compared with symptomatic tumors (Tables 2 and
3), similar results were obtained. However, incident
screen-detected patients were older (OR = 1.04 CI =
1.008-1.081), and their tumors exhibited apoptotic acti-
vity more frequently (OR = 5.06; CI = 1.71-14.94). Ad-
ditionally, the treatment delay was short in the case of
incident screen-detected carcinomas (OR = 0.47, CI =
0.23-0.95) (Table 2).Prevalent versus incident screen-detected carcinomas
Comparison of prevalent versus incident screen-detected
carcinomas (Table 4) showed that in prevalent carci-
nomas, the tumors were larger (1.64 ± 0.15 vs. 1.27 ±
0.17; p = 0.04) and the patients were younger (56.88 ±
0.65 vs. 59.71 ± 0.68, p < 0.01); the presence of lymph
node metastases did not differ between prevalent and
incident-detected cancers (Table 4). However, prevalent
tumors were less likely to be HER2/neu and Ki67 posi-
tive (O.R = 0.22; CI = 0.087-0.61 and OR = 0.36, CI =
0.17-0.77, respectively) and presented a longer delay
prior to receiving treatment after diagnosis (OR = 3.31;
CI = 1.65-6.62).
Table 2 Clinical-pathological prognostic features of disease
Incident (n = 65) vs. Symptomatic (n = 130) P value OR adjusted by tumor size
Mean age 59.7 ± 0.68 vs. 56.3 ± 1.14 p < 0.05 1.04 (1.01-1.08)
Mean size (cm) 1.27 ± 0.17 vs. 2.68 ± 0.15 p < 0.001 –
Lymph node positive 21.5% vs. 48.9% p < 0.001 0.78 (0.34-1.76)
Poorly differentiated tumors 32.8 vs. 39.7% N.S. 0.56 (0.27-1.17)
ER positive 89.1% vs. 57.4% p < 0.001 4.23 (1.61-11.12)
PR positive 78.2 vs. 36.4% p < 0.001 4.60 (2.11-10.03)
In situ carcinomas 11% vs. 1.5% p < 0.001 2.44 (0.42-13.87)
Apoptosis 66.7% vs. 38.5% p < 0.05 5.06 (1.71-14.94)
Bcl-2 81.3% vs. 62.7% p < 0.05 1.39 (0.89-2.19)
c-erb-B2 26.3% vs. 23% N.S. 0.86 (0.21-3.53)
Ki67 63% vs. 52.5% N.S. 1.96 (0.93-4.09)
Delay Diagnosis- treatment (>30 days) 35.4% vs. 57% p < 0.05 0.47 (0.23-0.95)
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false negative mammogram. In spite of the small number
of such cases, we found statistically significant differ-
ences in the percentage of cells that expressed Ki67 anti-
gens. Only 33% were positive in the group of false
negative mammograms versus 63% for the true incident
screen-detected carcinomas (OR = 0.29; CI = 0.08-0.98)
(Table 5).Survival by method of detection
Screen-detected carcinomas had the longest survival
period. This result was expected because the comparison
of survival time would be affected by lead time and other
biases. To minimize lead-time bias in the following ana-
lyses, we compared survival distributions by method of
detection for patients whose breast cancers were the
same size. After adjusting for tumor size, we found that
screen-detected carcinomas presented a decreased per-
centage of recurrences and better disease-free survival.Table 3 Clinical-pathological prognostic features of disease
Prevalent (n = 76) vs. Sym
Mean age 56.8 ± 0.65 vs. 56
Mean size (cm) 1.64 ± 0.15 vs. 2.6
Lymph node positive 25% vs. 48.
Poorly differentiated tumors 32.1% vs. 39
ER positive 87.5% vs. 57
PR positive 70.3% vs. 36
In situ carcinomas 13% vs. 1.5
Apoptosis 42.5% vs. 38
Bcl-2 75.4% vs. 62
c-erb-B2 7.4% vs. 26.
Ki67 38.5 vs. 52.5
Delay Diagnosis-treatment (>30 days) 64.5% vs. 5Thus, for tumors ≤ 2 cm, the percentage of recurrence
was 30% for symptomatic tumors, while it was only 6%
for screen-detected tumors (p < 0.05). When we selected
tumors > 2 cm, the percentages were 39% and 14%, re-
spectively (p < 0.05). Disease-free survival adjusted by
tumor size relative risk (RR) was 0.33 (CI = 95%: 0.15-
0.70).
When we introduced not only tumor stage but also
biological characteristics into the multivariate analysis,
the method of detection maintained its prognostic value
(RR = 0.42; CI = 0.19-0.93).
Comparison of prevalent vs. incident carcinomas
showed that survival was significantly shorter for inci-
dent cases (RR = 4.88, CI = 1.12-21, 19) (Figure 1). No
differences in survival were detected between incident
cases and symptomatic ones (RR = 0.57, CI = 0.46-3.96).
However, when we compared prevalent vs. symptomatic
carcinomas, survival was found to be significantly longer
for prevalent cases (OR = 0.34, CI 0.13-0.88). Therefore,
incident carcinomas constitute a type of screen-detectedptomatic (n = 130) P value OR adjusted by tumor size
.3 ± 1.14 N.S. 1.01 (0.98-1.03)
8 ± 0.15 p < 0.001 –
5% p < 0.001 0.54 (0.27-1.08)
.7% N.S. 0.55 (0.29-1.04)
.4% p < 0.001 4.56 (1.98-10.52)
.4% p < 0.001 3.65 (1.88-7.08)
% p < 0.001 8.30 (1.70-40.31)
.5% N.S. 1.45 (0.67-3.16)
.7% N.S. 1.52 (0.75-3.06)
3% p < 0.01 0.59 (0.31-0.90)
% N.S. 0.64 (0.34-1.22)
5% N.S. 1.51 (0.81-2.81)
Table 4 Clinical-pathological prognostic features of disease
Prevalent (n = 76) vs. Incident screened (n = 65) P value OR
Mean age 56.88 ± 0.65 vs. 59.71 ± 0.68 P < 0.01 0.91 (0.86-0.98)
Mean size (cm) 1.64 ± 0.15 vs. 1.27 ± 0.17 p < 0.05 1.44 (1.01-2.08)
Lymph node positive 25% vs. 21.5% N.S. 1.21 (0.55-2.66)
Poorly-differentiated tumors 32.1% vs. 32.8% N.S. 0.96 (0.49-1.90)
ER positive 87.5% vs. 89.1% N.S. 0.85 (0.27-2.64)
PR positive 70.3% vs. 78.2% N.S. 0.66 (0.28-1.52)
in situ carcinomas 13% vs. 11% N.S. 1.25 (0.44-3.51)
Apoptosis 42.5% vs. 66.7% N.S. 0.37 (0.12-1.11)
Bcl-2 75.4% vs. 81.3% N.S. 0.70 (0.28-1.77)
Ki67 38.5% vs. 63% p < 0.01 0.36 (0.17-0.77)
c-erb-B2 7.4% vs. 23% p < 0.01 0.22 (0.08-0.61)
Delay Diagnosis- treatment (>30 days) 64.5 vs. 35.4 p < 0.01 3.31 (1.65-6.62)
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lent carcinomas.
No event was detected in the 20 cases of false negative
mammograms.
Discussion
We found the method of detection to be an important
prognostic factor for breast cancer survival, even after
adjusting for tumor characteristics.
Because lead time manifests itself as an earlier stage of
disease, fixing the stage of disease reduces the magnitude
of lead-time bias. Such an adjustment, however, has little
or no effect on length bias. Cancers found via screening
include a higher proportion of slowly growing tumors,
some of which might never be found by other means;
this observation represents an extreme form of length
bias known as overdiagnosis bias. Some studies indicate
that the disease prognosis may be predestined at theTable 5 Clinical-pathological prognostic features of disease
False Negative mammograms (n
Mean age 60.8 + 1.1 vs. 5
Mean size (cm) 1.17 + 0.16 vs. 1
Lymph node positive 6.3% vs. 21
Poorly differentiated tumors 50% vs. 4
ER positive 95% vs. 8
PR positive 85.7% vs. 7
In situ carcinomas 6.3% vs. 1
Apoptosis 42.9% vs. 6
Bcl-2 84.6% vs. 8
c-erb-B2 15% vs. 23
Ki67 33.3% vs. 6
Delay Diag- treat (>30 days) 37.9% vs. 3
ER: estrogen receptor, PR: progesterone receptor.time of diagnosis, independent of the tumoral character-
istics at diagnosis [13,14]. The other biological character-
istics are potentially critical factors that determine the
aggressiveness of a tumor and, thus, could be used to
further quantify the length bias. The established profile
of aggressive breast tumors includes metastasis to re-
gional lymph nodes, loss of ERs and PRs, high prolifera-
tive rate and overexpression of c-erbB-2 oncogene
[15,16]. However, apoptosis has a strong association with
proliferation, and in previous studies, apoptosis in pri-
mary breast carcinomas was independently associated
with shorter survival [17,18]. However, bcl-2 expression
was statistically associated with a better clinical out-
come and with a number of favorable prognostic fea-
tures [19-21]. Our results indicate that screen-detected
breast carcinomas are significantly associated with several
features indicative of low malignant potential, as has been
described in other studies [9,22,23].= 20) vs. Incident (n = 65) P value OR
9.7 + 0.6 N.S. 1.04 (0.93-1.15)
.27 + 0.09 N.S. 0.79 (0.34-1.86)
.5% N.S. 0.24 (0.02-2.00)
0% N.S. 1.50 (0.50-4.49)
9% N.S. 1.59 (0.17-14.4)
8.2% N.S. 1.67 (0.32-8.52)
1% N.S. 0.55 (0.06-4.84)
6.7% N.S. 0.37 (0.06-2.15)
1.3% N.S. 1.26 (0.23-6.75)
.1% N.S. 0.41 (0.04-3.79)
3% p < 0.05 0.29 (0.08-0.98)
5.4% N.S. 1.09 (0.33-3.59)
Figure 1 Disease-specific survival distribution in screen-
detected carcinomas. The cumulative survival of patients in the
incident group (thick line) is significantly shorter than that of
patients in the prevalent group (thin line).
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cerous tumors detected by mammography screening
compared with women whose tumors were found by
other means might be explained not only by the smaller
tumor size detected by screening but by the more favor-
able biological features of these tumors. In our series,
cancerous tumors detected by screening were more
often HER2/neu negative. In addition, bcl-2 and estro-
gen and progesterone receptors were found to be posi-
tive at a significantly higher rate in screen-detected
tumors than in symptomatic tumors. Similar findings
were reported by Crosier et al. [24] and Dawson et al.
[9]. However, these features do not fully explain the ge-
nerally better outcomes of women with cancerous
tumors detected by mammography screening because
the mode of detection was an independent prognostic
variable in the multivariate analyses.
In the present study, breast carcinoma recurrence
rates were significantly lower among screened patients
compared with unscreened patients after adjusting for
tumor size. Two previous studies [25,26] have also
reported significant differences in 5-year recurrence
rates between screened and unscreened women. In
addition, our conclusions support those of other studies
[5,9] in showing that the method of detection is an inde-
pendent prognostic factor. As in the study by Joensuu
et al. [5], we adjusted the outcome for tumor size, the
number of axillary lymph nodes involved, tumor grade
and hormone receptor content, as well as for prognostic
factors, such as Her-2 status and Ki67. Even after adjust-
ing for all of these factors that might be expected to re-
flect the aggressiveness of tumor growth (and, hence,
length bias due to screening), we found that diagnosis by
a method other than mammographic screening was a
statistically significant independent predictor of shortdisease-free survival. These results would appear to con-
firm those of previous studies that have suggested that
screen detection is an independent prognostic factor for
both disease-specific survival [7-9] and distant recur-
rence [5]. Our results also show that in tumors < 2 cm,
the disease-specific survival of symptomatic cancer is
shorter than that in the screen-detected group. In fact,
Joensuu et al. [5] observed that in women aged 50–
69 years with node-negative tumors, the 10-year distant
disease-free survival rate was better in the screen-
detected cohort than in the symptomatically presenting
group (93% vs. 87% for tumors ≤1 cm). This survival
benefit is most likely due to differences in tumor biology
between screen-detected and symptomatic cancers.
Interestingly, this study clearly shows that incident
cancers are biologically different from prevalent ones.
No previous studies have measured the expression of
biological markers of prognosis in incident cancers. Inci-
dent cancers appeared to have worse prognosis than that
of prevalent cancers based on the expression of bio-
logical marker. Additional tumor characteristics com-
monly associated with aggressive clinical behavior in
breast cancer, such as positivity for Ki67 and HER2/neu,
were associated with incident-detected cancers, which
supports the hypothesis that incident cancers are bio-
logically more aggressive than their prevalent screen-
detected counterparts. Clearly, however, the size of
breast cancers increases with time, as prevalent cancers
were larger than incident cancers. The poorer outcomes
for incident cancers may be associated with their bio-
logic differences and more rapid tumor growth. In fact,
these incident carcinomas were found after a “normal”
mammogram, which suggests a faster growth rate for
these tumors. It is known that indices of rapid growth
are associated with breast cancer aggressiveness and
poorer prognosis [27,28].
It is possible that cancers diagnosed at the first screen-
ing round are subject to overdiagnosis and length bias;
thus, first-round screening may have a lesser effect on
breast cancer mortality. We also considered incident
cancers separately from cancers found in the symptom-
atic group. Nevertheless, we found similar survival dis-
tributions for incident cancers and cancers detected in
the symptomatic group.
In a previous work [29], a short, in-hospital, diagnostic
delay for breast carcinomas was associated with advanced
disease state and poor survival. In this series of patients,
we report a short treatment delay for incident tumors.
This delay most likely indicates that doctors give priority
to patients with a previous negative mammogram.
Conclusions
We conclude that prevalent screen-detected breast can-
cer is associated with a favorable prognostic profile.
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http://www.biomedcentral.com/1471-2407/12/604Physicians should know that patients whose breast can-
cers are detected in the first round of screening have a
higher probability of a better prognosis. Current treat-
ment paradigms do not consider the method of tumor
detection to be important when selecting systemic adju-
vant therapies. We feel that the mode of breast cancer
detection should be taken into account when determin-
ing individual patient management strategies. Studies
with larger series of patients are needed to corroborate
our findings and to identify new biological characteris-
tics associated with the prognosis of screen-detected
carcinomas.
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